©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 7, 2017; 23(17): 3017-3021
Published online May 7, 2017. doi: 10.3748/wjg.v23.i17.3017
Published online May 7, 2017. doi: 10.3748/wjg.v23.i17.3017
Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality
Hampig Raphael Kourie, Samer Tabchi, Marwan Ghosn, Department of Oncology, Faculty of Medicine, Saint Joseph University, Beirut 166830, Lebanon
Author contributions: Kourie HR and Tabchi S initiated and wrote the editorial; Ghosn M reviewed the manuscript.
Conflict-of-interest statement: Authors do not have any conflict of interest.
Correspondence to: Marwan Ghosn, MD, Department of Oncology, Faculty of Medicine, Saint Joseph University, Alfred Naccache, Beirut 166830, Lebanon. marwanghosnmd@yahoo.com
Telephone: +961-3-226842 Fax: +961-1-613397
Received: July 28, 2016
Peer-review started: August 2, 2016
First decision: September 20, 2016
Revised: March 11, 2017
Accepted: March 31, 2017
Article in press: March 31, 2017
Published online: May 7, 2017
Processing time: 282 Days and 1.7 Hours
Peer-review started: August 2, 2016
First decision: September 20, 2016
Revised: March 11, 2017
Accepted: March 31, 2017
Article in press: March 31, 2017
Published online: May 7, 2017
Processing time: 282 Days and 1.7 Hours
Core Tip
Core tip: Immune checkpoint inhibitors represent new promising anti-cancer therapies, rapidly approved in different malignancies and settings. We aimed in this editorial to report all the ongoing and published trials evaluating these agents in gastro-intestinal malignancies, to focus on the past expectations and the reality of the results and finally, to discuss the future perspectives of these agents in this field.